Board Change

RNS Number : 4045X

Scancell Holdings Plc

10 August 2018

 

10 August 2018

Scancell Holdings Plc

("Scancell" or the "Company")

Board Change

Scancell Holdings Plc (AIM: SCLP) today announces that Kate Cornish-Bowden will be stepping down as Non-Executive Director as of 31 August 2018 after seven years on the Board of the Company.  

Dr John Chiplin, Chairman of Scancell, commented:

"Kate has made an important contribution in guiding Scancell through its formative years during her time on the Board and in her role as chairman of the Remuneration Committee. We would like to thank her for her hard work and wish her all the best for the future."

For Further Information:

Scancell Holdings Plc
Dr John Chiplin, Chairman		[phone]
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser and Corporate broker)
Freddy Crossley/Emma Earl		[phone]
FTI Consulting Mo Noonan/Simon Conway		[phone]

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They can be used as monotherapy or in combination with checkpoint inhibitors. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival. 

·     SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·     SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2. 

Moditope® represents a completely new class of potent and selective immunotherapy agents. It stimulates the production of killer CD4+ T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·      Modi-1 is being developed for the treatment of triple negative breast cancer, ovarian cancer and sarcomas.

For further details, please see our website:  www.scancell.co.uk

 

END

 

 

BOAFKLLBVVFBBBF